Syngene Q1 FY27: Revenue up about 19%, consolidated PAT swings to profit
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts less than Nifty Smallcap 250 and 2.7 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene Q1 FY27 results: consolidated revenue grew 18.8% YoY to Rs 8,745 million; standalone revenue rose 20.5% to Rs 7,993 million. Consolidated PAT swung to Rs 867 million profit from a Rs 90 million loss YoY. Standalone PAT slipped into a small loss of Rs 21 million versus Rs 740 million profit a year ago, weighed down by a Rs 135 million exceptional charge for termination benefits and a Rs 501 million forex loss. Board approved voluntary liquidation of subsidiary Syngene Manufacturing Solutions Ltd and proposed a Rs 1.25 per share final dividend.
Mixed quarter — consolidated turnaround is positive but standalone dip into loss and large forex hit may cap upside; US biologics expansion and dividend are positives.